Dose reduction in TPF chemotherapy − A retrospective review −

DOI
  • HARATA Ikuma
    Department of Otorhinolaryngology, Ichinomiya Municipal Hospital
  • IJICHI Kei
    Department of Otolaryngology - Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences
  • MORIBE Kazuho
    Department of Otorhinolaryngology, Ichinomiya Municipal Hospital
  • MURAKAMI Shingo
    Department of Otolaryngology - Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences

Bibliographic Information

Other Title
  • TPF 療法における減量投与についての検討

Description

<p>We retrospectively reviewed 82 patients with progressive head and neck squamous cell carcinoma who were treated with induction chemotherapy using docetaxel, cisplatin, and 5-FU in our institute from Apr 2007 to Mar 2012, to determine whether a dose reduction could reduce adverse events, and affect the treatment outcome. The study population included patients who were > 70 years of age who could not continue induction chemotherapy with the standard therapeutic dose due to adverse events. A reduction in the dose that was used in the first cycle seemed to be essential for those patients. A 10% dose reduction of 3 agents (docetaxel, cisplatin, 5-FU) was equivalent to a 20% dose reduction of 2 agents (docetaxel, cisplatin) with regard to the therapeutic effect and the tolerability of adverse events, when the dose amount at the second cycle was reduced after grade IV neutropenia in the first cycle.</p>

Journal

  • jibi to rinsho

    jibi to rinsho 63 (1), 7-14, 2017-01-20

    JIBI TO RINSHO KAI

Keywords

Details 詳細情報について

  • CRID
    1390282679548160000
  • NII Article ID
    130006319071
  • DOI
    10.11334/jibi.63.1_7
  • ISSN
    21851034
    04477227
  • Text Lang
    ja
  • Data Source
    • JaLC
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top